SCHEMBL10313508

SCHEMBL10313508

Cc1ccc(-c2c(C)nn3c(=O)cc(-c4ccc(C(F)(F)F)cc4)[nH]c23)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAT P00750 3/20 0.42
NPC1 O15118 1/20 0.41
MAPT P10636 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ALDH1A1 P00352 1/20 0.41
GLA P06280 1/20 0.41
GAA P10253 1/20 0.41
HPGD P15428 1/20 0.41
ATM Q13315 1/20 0.41
PDE2A O00408 3/20 0.41
ALPL P05186 1/20 0.39
ALPI P09923 1/20 0.39
MAT2A P31153 1/20 0.39
RAD51 Q06609 2/20 0.38
NPBWR1 P48145 1/20 0.38
PDE5A O76074 1/20 0.37
CCNB2 O95067 1/20 0.37
CDK1 P06493 1/20 0.37
CCNB1 P14635 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10275316 0.88 KIF11 (0.43) PLATNPC1MAPTRAB9ASMN1; SMN2
SCHEMBL17298709 0.87 MEN1 (0.43) PLATNPC1MAPTRAB9ASMN1; SMN2
SCHEMBL10276231 0.86 CNR1 (0.41) PLATNPC1MAPTRAB9ASMN1; SMN2
SCHEMBL13516556 0.85 ADORA2A (0.41) PLATNPC1MAPTRAB9ASMN1; SMN2
SCHEMBL10313475 0.84 ALPL (0.41) PLATALDH1A1GLAGAAHPGD
SCHEMBL10276122 0.83 PLAT (0.40) PLATNPC1MAPTRAB9ASMN1; SMN2
SCHEMBL10275482 0.83 PLAT (0.40) PLATNPC1MAPTRAB9ASMN1; SMN2
SCHEMBL10275680 0.82 PLAT (0.38) PLATNPC1MAPTRAB9ASMN1; SMN2
SCHEMBL10275442 0.82 ARF6 (0.41) PLATNPC1MAPTRAB9ASMN1; SMN2
SCHEMBL10313454 0.81 ALDH1A1 (0.41) PLATMAPTALDH1A1GLAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF XU LIFENG (US) 2012-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF TYMP, TYMS, ADORA3 PLAT 2180/4885NPC1 1381/4885MAPT 750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.